Resmetirom ‘has potential to be first medication approved’ for patients with NASH
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.“The primary and key secondary endpoints from the study were achieved,” Stephen Harrison, MD, medical director for Pinnacle Clinical Research in San Antonio and visiting professor of hepatology at Oxford University, told Healio. “Resmetirom was safe and well tolerated and provided significant reductions in liver fat, low-density lipoprotein cholesterol and otherRead More
